WASHINGTON — For the better part of three decades, Americans reaching for sunscreen have been handed a weaker shield against the sun than the one sold routinely in European and Asian pharmacies. That gap began to close on Tuesday, when the Food and Drug Administration cleared bemotrizinol, a broad-spectrum ultraviolet filter, for use in over-the-counter sunscreens sold in the United States. The decision, confirmed this week, marks the first new sunscreen active ingredient the agency has added to its monograph since the late 1990s.
Bemotrizinol is not new to the world. It has been used safely in Europe, Australia and parts of Asia for decades, valued because it absorbs both UVA and UVB rays, passes only minimally through the skin and rarely causes irritation. The ingredient is cleared for adults and for children as young as six months, and DSM Nutritional Products, the company that petitioned the agency, may use it at concentrations of up to 6 percent, the terms laid out in the announcement.
The delay was never really about the chemistry. The United States is one of the only wealthy countries that regulates sunscreen as an over-the-counter drug rather than a cosmetic, which means every active ingredient must clear the same daunting evidentiary bar as a medicine. Europe, which treats sunscreens as cosmetic products, has been able to adopt newer filters far faster. The result has been a measurable shortfall in American protection, particularly against the longer UVA wavelengths linked to premature skin ageing and cancer.
That shortfall carries a human cost. Melanoma remains among the more common cancers diagnosed in the United States, and dermatologists have argued for years that Americans were being denied filters offering better and more cosmetically elegant coverage, the kind of product people are actually willing to wear every day. A sunscreen that feels heavy or greasy is a sunscreen that stays in the cabinet, and the formulas common abroad have long been lighter on the skin.
Tuesday’s clearance came unusually quickly once it finally began, completed in roughly seven months under a streamlined pathway Congress created to break the logjam. The speed is its own quiet indictment, suggesting the decades of waiting owed less to any genuine doubt about safety than to a review process that had calcified, much as the agency drew criticism over its handling of scientific evidence in other recent disputes.
For much of the rest of the world, the news will read as the United States catching up rather than leading. The filters now reaching American consumers have protected sunbathers on Mediterranean and Australian beaches since before many of today’s buyers were born, a sequence of events widely covered on Tuesday. The country that prides itself on leading the world in medicine has spent a generation importing tourists’ suitcases full of sunscreen instead of approving the chemistry inside them.
The bemotrizinol decision fits a broader, halting effort to modernise how the FDA handles lower-risk products. The agency recently moved to open an early access pathway for a breakthrough cancer therapy, another case in which sustained pressure, rather than any new scientific finding, was what finally shook loose a long-stalled approval. The pattern suggests the bottleneck has been institutional habit more than caution.
Consumers should not expect their bottles to change overnight. Bringing bemotrizinol into American products will require reformulation, testing and new labelling, and the higher cost of advanced filters may keep them out of the cheapest sunscreens at first. Drugmakers with treatments still awaiting FDA decisions are watching closely to see whether the faster review pathway proves durable or evaporates once the headlines fade.
Still, the approval matters well beyond the sunscreen aisle. It is a small test of whether a regulator famous for caution can move at the pace of the everyday products it governs, and of whether the United States is willing to borrow solutions long proven abroad rather than insisting on reinventing each one from scratch. On both counts, the answer this week was a tentative yes.
What remains unclear is how long American shoppers will actually wait to feel the difference. The agency has changed the rule; the chemical suppliers, manufacturers, retailers and price tags will decide when it reaches the beach bag. Until a bottle carrying the new filter sits on an ordinary drugstore shelf at a price working families will pay, the gap the FDA narrowed on paper this week stays open in practice.
